Compare · MOVE vs TMDX
MOVE vs TMDX
Side-by-side comparison of Corvex Inc. (MOVE) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOVE and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 12.6x MOVE ($256.8M).
- Over the past year, MOVE is up 72.0% and TMDX is down 18.7% - MOVE leads by 90.7 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- TMDX has more recent analyst coverage (19 ratings vs 0 for MOVE).
- Company
- Corvex Inc.
- TransMedics Group Inc.
- Price
- $8.74-2.78%
- $93.68+0.10%
- Market cap
- $256.8M
- $3.25B
- 1M return
- -32.14%
- +25.93%
- 1Y return
- +72.01%
- -18.71%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 5
- 5
- Recent ratings
- 0
- 19
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest MOVE
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Corvex Inc.
- Corvex Reports Second Quarter 2026 Results and Provides Business Update
- Corvex to Host Second Quarter 2026 Earnings Call on Friday, August 14, 2026
- Corvex Signs Multi-Year Agreement to Provide NVIDIA Blackwell GPUs
- SEC Form EFFECT filed by Corvex Inc.
- SEC Form 424B7 filed by Corvex Inc.
- Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations
- SEC Form S-1 filed by Corvex Inc.
- Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)